Home Home Wellness News Immune-Focused Drug New Weapon Against Melanoma

Denture Repairs

Denture Repair Same Day Done On Premises, Jupiter Florida, Dr. Mona Sims 561 747-7172

Dr. Mona Sims DDS

Caring for patients 25 years, same location in Jupiter, Florida for 15 years.

Have a question? Ask Dr. Sims

Advanced Dental Concepts of Jupiter
Dr. Mona Sims DDS

651 W Indiantown Rd Suite A Jupiter, FL 33458
(561) 747-7172

Home Home Wellness News Immune-Focused Drug New Weapon Against Melanoma
Immune-Focused Drug New Weapon Against Melanoma
Wellness - Latest Wellness News
Jupiter, FL Dentist

By Robert Preidt

HealthDay Reporter

MONDAY, Sept. 11, 2017 (HealthDay News) -- New research suggests that Opdivo -- a drug that works with the immune system to fight melanoma -- is more effective than the current standard of care for patients who've had surgery to remove advanced tumors.

The international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.

Patients were treated at 130 medical centers across 25 countries. All underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care.

Both drugs are "immunotherapies," which work by boosting the immune system's ability to spot and destroy tumor cells.

After a year of treatment, 71 percent of patients in the Opdivo group were alive without any recurrence of the disease, compared with 61 percent of those treated with Yervoy. And at 18 months, the rate was 66 percent for Opdivo and 53 percent for Yervoy, the findings showed.

According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.

"Our results demonstrate that [Opdivo] is more effective in treating patients with stage III and IV melanoma, cutting the risk of relapse by a third," lead researcher Dr. Jeffrey Weber, professor of medicine at NYU School of Medicine, said in a university news release.

"Results like this will change how we practice medicine. Hopefully, physicians will embrace the use of [Opdivo] in these high-risk patients as adjuvant therapy," added Weber, who also helps direct NYU's Perlmutter Cancer Center in New York City.

One cancer surgeon who reviewed the findings was impressed.

"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo," said Dr. Gary Deutsch. He is a surgical oncologist at Northwell Health's Imbert Cancer Center in Bay Shore, N.Y.

"Not only did these patients have a better survival outcome at one year, but they had only one-third the side effects compared to Yervoy," Deutsch said.

Gentle Dentistry With A Woman's Touch

WebMD Health News - DrMonaSims.com - Gentle Dentistry With A Woman's Touch

Read Full Article